Objective:
To evaluate the impact of home optical coherence tomography (OCT) on monitoring and treatment decisions in neovascular age-related macular degeneration (nAMD).
Key Findings:
- Home OCT may extend treatment intervals from 8 weeks to approximately 15 weeks in treatment-experienced patients.
- Clinicians using home OCT data may treat patients approximately one week earlier than in routine practice.
- Home OCT helps identify clinically significant fluctuations in disease activity that may be missed in office visits.
Interpretation:
Home OCT provides continuous monitoring of nAMD, potentially improving treatment responsiveness and patient outcomes.
Limitations:
- The ongoing Protocol AO trial's results are pending.
- Home OCT is intended to augment, not replace, traditional clinical care.
Conclusion:
Home OCT could enhance nAMD management by offering additional monitoring and reassurance, particularly for anxious patients or those with extended treatment intervals.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.